Selective HDAC3 inhibitors
Provided herein are inhibitors of HDAC3, as well as methods of treatment comprising administering those compounds to a subject in need thereof.
1. A compound selected from the following:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
3. A method of treating type 2 diabetes, Huntington's disease, spinal and bulbar muscular atrophy, or lung cancer in a subject comprising administering to the subject a compound of claim 1 or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the disease is type 2 diabetes.
5. The method of claim 3 , wherein the disease is Huntington's disease.
6. The method of claim 3 , wherein the disease is spinal and bulbar muscular atrophy.
7. The method of claim 3 wherein the disease is lung cancer.
8. The method of claim 3 , wherein the subject is human.
9. A compound which is:
or a pharmaceutically acceptable salt thereof.
10. A compound which is:
or a pharmaceutically acceptable salt thereof.
11. A compound which is:
or a pharmaceutically acceptable salt thereof.